http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2544718-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_11853964b5a94425431547dba6253b1f |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-49 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N11-167 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N11-162 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-49 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N11-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-86 |
| filingDate | 2004-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5388e40e81a5047dca44545ca6c0b4ae http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08291ff72aca4f6208783bb5b884fed3 |
| publicationDate | 2015-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2544718-T3 |
| titleOfInvention | Protocol to control platelet inhibition |
| abstract | A method comprising: a first blood sample with a fibrin activator comprising at least one of the group of reptilase and Factor XIIIa, and testing the first blood sample to determine a characteristic of the first blood sample in substantial absence of activation platelet, in which the first characteristic of the blood sample represents a contribution of fibrin to homeostasis; a second blood sample with an ADP site activator or an A2 thromboxane site activator, and test the second blood sample to determine a characteristic of the second blood sample in the presence of an antiplatelet therapy, in which the second characteristic of the blood sample represents a contribution to homeostasis of activated platelets in the presence of antiplatelet therapy; a third blood sample to neutralize anticoagulant therapy and to determine a characteristic of the third blood sample in the presence of substantially uninhibited platelet activation, in which the characteristic of the third blood sample represents a contribution to the hemostasis of platelet activation substantially complete; and determine a parameter indicating the efficacy of antiplatelet therapy based on the first, second and third characteristics of the blood sample. |
| priorityDate | 2003-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 107.